

Date: 12.02.2025

To,

M/s. Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai - 400 001

Security Code: 524654

Dear Sir / Madam,

Sub: Outcome of Board Meeting held on February 12th, 2025

This is to inform that the Board of the Directors at their meeting held on Wednesday, February 12th, 2025, have:

1. Approved the unaudited Standalone and Consolidated Financial Results for the quarter ended December 31st, 2024.

The Board Meeting commenced at 03.30 PM and concluded at 05:15 PM

Kindly take the aforesaid information on record in compliance of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015.

Thanking you.

For Natural Capsules Limited

Shilpa Burman
Company Secretary & Compliance Officer



P. CHANDRASEKAR LLP

Chartered Accountants

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS,

TO

The Board of Directors,
Natural Capsules Limited,
Bangalore.

1. We have received the accompanying statement of unaudited financial results of **M/s. NATURAL CAPSULES LIMITED** ("the company") for quarter ended December 2024 and year to date from April 01, 2024 to 31st December 2024 ("the Statement"), which are included in the accompanying statement of unaudited Financial results. This statement has been prepared by the company pursuant to the requirement of Regulation 33 of the securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended.
2. This statement is the responsibility of the company's Management and has been approved by the Board of Directors. This Statement has been prepared in accordance with the recognition and measurement principles laid down in the IND AS 34 "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Bangalore / Chennai / Hyderabad

Head Office:

S-512-514, Manipal Centre, #47, Dikenson Road, Bangalore – 560042

☎ : 080-25585443 / 25597494

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard as specified under section 133 of the Companies Act 2013 read with relevant rules issued thereunder other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended including the manner in which it is to be disclosed , or that it contains any material misstatement.

For P. Chandrasekar LLP
Chartered Accountants
FRN No: 000580S/S20006



Arun R
Partner

Membership No: 208425
UDIN : 25208425BBIKDX2546
Place - Bangalore
Date:12th February 2025



NATURAL CAPSULES LIMITED

TRIDENT TOWERS, 4TH FLOOR, NO. 23,100 FEET ROAD, JAYANAGAR II BLOCK, BANGALORE-560 011
Ph. 26671571/573, Fax 26671562, E-mail : Info@naturalcapsules.com / CIN: L85110KA1993PLCO14742

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER / NINE MONTHS ENDED DEC 31, 2024.

Rs. (in Lakhs)

Sl. No.	PARTICULARS	Quarter Ended			Nine Months Ended		Year Ended
		31st Dec 2024	30th Sep 2024	31st Dec 2023	31st Dec 2024	31st Dec 2023	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
1	Revenue from operations	4,341.18	4,102.98	3,838.23	12,357.74	11,360.25	15,380.63
2	Other Income	115.15	76.96	70.62	268.60	189.02	314.57
3	Total Income (1+2)	4,456.32	4,179.94	3,908.85	12,626.34	11,549.27	15,695.20
4	Expenses						
	a) Cost of Material consumed	2,146.35	2,110.83	2,126.25	6,298.89	6,146.58	8,331.61
	b) (Increase) / Decrease in stock in trade	53.15	-141.59	-146.13	-134.91	-500.66	-613.40
	c) Purchase of stock-in-trade	-	-	-	-	-	-
	d) Employees benefits expense	372.17	320.55	309.93	1,015.82	885.25	1,231.79
	f) Finance cost	138.58	154.34	120.35	438.54	356.70	494.83
	g) Depreciation	213.83	215.54	216.32	638.66	642.95	856.85
	h) Other Expenses	1,310.95	1,318.78	1,053.61	3,752.91	3,203.74	4,354.06
	Total Expenses	4,235.03	3,978.45	3,680.33	12,009.91	10,734.57	14,655.73
5	Profit from ordinary activities after finance costs but before exceptional items	221.29	201.49	228.52	616.43	814.70	1,039.47
6	Exceptional Items Income / (Expenses)	-	-	-	-	-	-
7	Profit from ordinary activities before tax	221.29	201.49	228.52	616.43	814.70	1,039.47
8	Tax Expense	50.97	109.27	58.68	207.98	203.18	258.97
	- Current Tax	42.23	61.45	49.00	149.57	164.80	197.13
	- Income tax (Prior year)	-0.00	-0.00	0.00	0.00	0.00	0.00
	- Deferred Tax	8.75	47.83	9.68	58.41	38.39	61.84
9	Net Profit (+) / Loss (-) from ordinary activities after tax	170.32	92.22	169.84	408.45	611.52	780.50
10	Other Comprehensive income (OCI)						
	a) Items that will not be reclassified to profit or loss (net of tax)	-	-	-	-	-	26.09
	b) Items that will be reclassified to profit or loss (net of tax)	-	-	-	-	-	-
11	Total Comprehensive Income (OCI) for the period	170.32	92.22	169.84	408.45	611.52	806.58
12	Paid-Up Equity Share Capital (face value per share Rs.10/-)	1,034.12	1,024.87	933.18	1,034.12	933.18	933.18
13	Earnings Per Share of (before & after extraordinary items) Rs. 10/-						
	(a) Basic	1.65	0.90	1.81	3.95	6.55	8.67
	(b) Diluted	1.65	0.90	1.81	3.95	6.55	8.67

Note:

- The unaudited standalone financial results of the Company for the quarter / nine months ended 31st December, 2024 have been approved by the Board of Directors of the Company at its meeting held on 12th February, 2025. The results for the quarter / nine months ended 31st December, 2024 presented have been reviewed by the Statutory Auditors of the Company. An unqualified opinion has been issued by them thereon.
 - The unaudited standalone financial results for the quarter / nine ended 31st Decemehr, 2024 have been prepared above in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules 2016. The above audited standalone Financial results are filed with Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchange Website.
 - During the Quarter, Nomination, Remuneration & Compensation Committee (NRC) of the company have approved the allotment of a total of 92,500 Equity shares of face value Rs.10/- each fully paid up against the exercise of vested Options of Employee stock option plan 2018. These shares shall rank Pari-passu, in all respects with the existing equity shares of the company.
 - Utilization of preferential issue funds by the Natural Capsules Ltd as on 31st December, 2024 is as follows: (Rs. In Lacs)
- | | |
|---|---------|
| Particulars | |
| Amount received (Including balance in Escrow A/c) | 2921.33 |
| Amount Spent | 2921.33 |
| Balance available as on 31.12.2024 | Nil |
- There is no deviation in the use of proceeds from the objects stated in the offer documents of the preferential issue.
- Previous years figures have been regrouped wherever necessary.
 - Position of investor complaints for the quarter ended 31st December, 2024
- | | |
|-----------------------------|-----|
| Particulars | |
| Pending as on 30.09.2024 | Nil |
| Received during the quarter | Nil |
| Resolved during the quarter | Nil |
| Pending as on 31.12.2024 | Nil |

For and on behalf of the Board

Sunil L. Mundra
Managing Director
DIN:00214304
Place : Bangalore
Date : 12-02-2025



P. CHANDRASEKAR LLP

Chartered Accountants

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS,

TO

The Board of Directors,
Natural Capsules Limited
Bangalore

1. We have received the accompanying statement of Consolidated unaudited financial results of **M/s. NATURAL CAPSULES LIMITED** (the Parent) and its subsidiaries (the Parent and its subsidiaries together referred to as the Group), for the quarter ended December 2024 and year to date from April 01, 2024 to 31st December 2024 ("the Statement"), which are included in the accompanying statement of consolidated unaudited Financial results. This statement has been prepared by the company pursuant to the requirement of Regulation 33 of the securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended.
2. This statement is the responsibility of the company's Management and has been approved by the Board of Directors. This Statement has been prepared in accordance with the recognition and measurement principles laid down in the IND AS 34 "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.



Bangalore / Chennai / Hyderabad

Head Office:
S-512-514, Manipal Centre, #47, Dikenson Road, Bangalore - 560042
☎ : 080-25585443 / 25597494

4. The Statement includes the results of the following entities:

Name of the Entity	Relationship
Natural Phyto Pharma Private Limited	Subsidiary
Natural Biogenex Private Limited	Subsidiary

5. Based on our review conducted as above and based on the consideration of the review reports of the other auditors as given below in point no.6, nothing has come to our attention that causes us to believe that the Statement, prepared in accordance with applicable Indian accounting standards and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of one subsidiary included in the consolidated unaudited financial results, whose interim financial results reflect total assets of Rs.2.44 lacs ,total revenues of Rs. Nil for the nine months ended 31 December 2024, total net profit after tax of Rs. Nil for the nine months ended 31st December 2024 as considered in the Statement. These interim financial results have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports furnished by the management. In our opinion and according to the Information and explanations given to us by management, these financial statements and other financial information are not material to the Group. Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the financial information certified by management.

For P. Chandrasekar LLP
Chartered Accountants
FRN No: 000580S/S20006

Arun R
Partner

Membership No: 208425
UDIN: 25208425BBIKDY2861
Place - Bangalore
Date: 12th February 2025



NATURAL CAPSULES LIMITED

TRIDENT TOWERS, 4TH FLOOR, NO. 23, 100 FEET ROAD, JAYANAGAR II BLOCK, BANGALORE-560 011
Ph. 26671571/573, Fax 26671562, E-mail : Info@naturalcapsules.com / CIN: L85110KA1993PLCO14742

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER / NINE MONTHS ENDED DEC 31, 2024

Rs.(in lakhs)

Sl. No.	PARTICULARS	Quarter Ended			Nine Months Ended		Year Ended
		31st Dec 2024	30th Sep 2024	31st Dec 2023	31st Dec 2024	31st Dec 2023	31st Mar 2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from operations	4,382.72	4,122.45	3,998.45	12,423.51	11,519.77	15,542.00
2	Other Income	10.99	10.59	49.82	39.94	101.78	193.62
3	Total Income (1+2)	4,393.71	4,133.04	4,048.27	12,463.45	11,621.55	15,735.62
4	Expenses						
	a) Cost of Material consumed	2,230.79	2,124.05	2,126.25	6,393.20	6,145.88	8,400.39
	b) (Increase) / Decrease in stock in trade	-2.22	-141.19	-146.13	-183.18	-500.66	-681.50
	c) Purchase of stock-in-trade	-	-	147.97	-	147.97	147.97
	d) Employees benefits expense	381.78	329.12	309.93	1,041.58	885.25	1,237.20
	f) Finance cost	154.09	164.61	124.11	467.46	373.03	512.94
	g) Depreciation	233.30	234.90	218.59	696.18	646.47	866.78
	h) Other Expenses	1,345.76	1,359.98	1,088.24	3,858.24	3,261.63	4,446.65
	Total Expenses	4,343.50	4,071.48	3,868.96	12,273.47	10,959.57	14,930.43
	Profit from ordinary activities after finance costs but before exceptional items	50.21	61.56	179.32	189.97	661.97	805.19
5	Exceptional Items Income / (Expenses)	-	-	-	-	-	-
6	Profit from ordinary activities before tax	50.21	61.56	179.32	189.97	661.97	805.19
8	Tax Expense	39.64	122.79	58.74	180.31	203.18	249.84
	- Current Tax	41.64	74.54	49.06	149.57	164.80	197.13
	- Income tax (Prior year)	-	-	-	-	-	-
	- Deferred Tax	-1.99	48.25	9.68	30.74	38.39	52.71
9	Net Profit (+) / Loss (-) from ordinary activities after tax	10.57	-61.22	120.57	9.67	458.79	555.35
10	Other Comprehensive income (OCI)						
	a) Items that will not be reclassified to profit or loss (net of tax)	-	-	-	-	-	26.09
	b) Items that will be reclassified to profit or loss (net of tax)	-	-	-	-	-	-
11	Total Comprehensive Income (OCI) for the period	10.57	-61.22	120.57	9.67	458.79	581.43
12	Paid-Up Equity Share Capital (face value per share Rs. 10/-)	1,034.12	1,024.87	933.18	1,034.12	933.18	933.18
13	Earnings Per Share of (before & after extraordinary items) Rs. 10/-						
	(a) Basic	0.10	-0.60	1.29	0.09	4.92	6.25
	(b) Diluted	0.10	-0.60	1.29	0.09	4.92	6.25

Note:

1 The unaudited consolidated financial results of the Company for the quarter/nine months ended 31st Dec, 2024 have been approved by the Board of Directors of the Company at its meeting held on 12th February 2025. The results for the quarter / nine months ended 31st December, 2024 presented have been reviewed by the Statutory Auditors of the Company. An unqualified opinion has been issued by them thereon.

2 The unaudited consolidated financial results for the quarter/nine months ended 31st December, 2024 have been prepared above in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules 2016. The above unaudited consolidated Financial results are filed with Stock Exchanges under Regulation 33 of SEBI (Listing and Other Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchange Website.

3 During the Quarter, Nomination, Remuneration & Compensation Committee (NRC) of the company have approved the allotment of a total of 92,500 Equity shares of face value Rs.10/- each fully paid up against the exercise of vested Options of Employee stock option plan 2018. These shares shall rank Pari-passu, in all respects with the existing equity shares of the company.

4 Utilization of preferential issue funds by the Natural Capsules Ltd as on 31st December, 2024 is as follows:

Particulars	Rs. In Lakh
Amount received (Including balance in Escrow A/c)	2,921.33
Amount Spent	2,921.33
Balance available as on 31.12.2024	-

There is no deviation in the use of the proceeds from the objects stated in the offer documents for the preferential issue.

5 Previous years figures have been regrouped wherever necessary.

6 Position of investor complaints for the quarter ended 31st December, 2024

Particulars	
Pending as on 30.09.2024	Nil
Received during the quarter	Nil
Resolved during the quarter	Nil
Pending as on 31-12-2024	Nil

For and on behalf of the Board

Sunil L. Mundra
Managing Director
DIN: 00214304
Place: Bangalore
Date : 12-02-2025

